Therapy
Research And Development
Health

Sangamo Therapeutics

$11.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (0.95%) As of 10:53 AM EDT today
+$0.11 (0.95%) Today

Why Robinhood?

You can buy or sell SGMO and other stocks, options, ETFs, and crypto commission-free!

About SGMO

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. Read More The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Employees
302
Headquarters
Richmond, California
Founded
1995
Market Cap
1.19B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
3.71M
High Today
$11.87
Low Today
$11.61
Open Price
$11.70
Volume
403.72K
52 Week High
$19.25
52 Week Low
$6.26

Collections

Therapy
Research And Development
Health
Biotechnology
Engineering
Technology

SGMO News

Washington PostJul 8

MDC, Sangamo Therapeutics rise; Apple, F5 Networks decline

76
BenzingaJul 8

Why Is Sangamo Therapeutics Stock Moving?

638
Yahoo FinanceJun 19

Here’s What Hedge Funds Think About Sangamo Therapeutics, Inc.

782

SGMO Earnings

-$0.41
-$0.11
$0.18
$0.48
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours

Popular Stocks

More SGMO News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.